Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders-Reference-Cited by-同舟云学术

Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders

Published:2017-09-26 Issue:2 Volume:17 Page:197-205
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Pompili Maurizio¹,Verzura Claudio²,Trovini Giada²,Buscajoni Andrea²,Falcone Giulia²,Naim Stefano²,Nardella Adele²,Sorice Serena²,Baldessarini Ross J³,Girardi Paolo¹

Affiliation:

1. Department of Neurosciences, Mental Health and Sensory Organs, Suicide Prevention Center, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy

2. Psychiatry Residency Training Program, Faculty of Medicine and Psychology, Sapienza University of Rome, Rome, Italy

3. Department of Psychiatry, Harvard Medical School; International Consortium for Bipolar and Psychotic Disorders Research, Mailman Research Center, McLean Hospital, Boston, MA, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2017.1379989

Reference42 articles.

1. Chemotherapy in Psychiatry

2. Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity

3. The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia

4. Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature

5. A 6-week, double-blind, placebo- and haloperidol-controlled, phase II study of lurasidone in patients with acute schizophrenia

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent Advances in representative small-molecule DRD2 inhibitors: Synthetic Routes and clinical applications;European Journal of Medicinal Chemistry;2024-11

2. Efficacy and Safety of Lurasidone vs. Quetiapine XR in Acutely Psychotic Patients With Schizophrenia in Korea: A Randomized, Double-Blind, Active-Controlled Trial;Psychiatry Investigation;2024-07-25

3. Post-marketing safety concerns with lumateperone: a pharmacovigilance analysis based on the FDA adverse event reporting system (FAERS) database;Frontiers in Pharmacology;2024-05-09

4. Microneedle-Assisted Transdermal Delivery of Lurasidone Nanoparticles;Pharmaceutics;2024-02-22

5. ANTIPSYCHOTIC DRUGS: THREE GENERATIONS OF ANTIPSYCHOTICS;ARMENIAN JOURNAL OF MENTAL HEALTH;2024